Nectar Lifesciences Limited

NSE:NECLIFE.NS

44.08 (INR) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

2024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12015 Q42015 Q32014 Q42014 Q3
Revenue 3,592.9974,413.7434,521.7113,979.5713,941.1633,878.9313,441.1943,886.4044,030.1664,762.2664,429.953,645.6333,850.4713,494.8753,773.9524,267.8973,896.2465,647.3316,479.6135,783.5255,753.3217,956.3137,326.0417,238.6335,307.660000
Cost of Revenue 2,767.8923,465.6643,643.5952,877.8722,791.6752,906.1752,704.0633,086.4622,896.0864,959.3973,250.462,641.0422,844.1513,715.4812,783.7783,295.5893,062.4225,772.585,220.9854,551.2054,430.8277,941.8365,879.9135,862.7894,023.6120000
Gross Profit 825.105948.079878.1161,101.6991,149.488972.756737.131799.9421,134.08-197.1311,179.491,004.5911,006.32-220.606990.174972.308833.824-125.2491,258.6281,232.321,322.49414.4771,446.1281,375.8441,284.0480000
Gross Profit Ratio 0.230.2150.1940.2770.2920.2510.2140.2060.281-0.0410.2660.2760.261-0.0630.2620.2280.214-0.0220.1940.2130.230.0020.1970.190.2420000
Reseach & Development Expenses 0000026.5400030.700024.3500024.4600000000000
General & Administrative Expenses 00000000000000000000000000000
Selling & Marketing Expenses 00000000000000000000000000000
SG&A 581.674610.043609.948630.021187.962597.858525.63683.308529.223578.482520.922557.768468.964595.702202.929185.246175.045201.614213.708213.184199.654187.378208.365215.727200.580000
Other Expenses 5.50814.6844.802106.0834.731179.248132.398107.1033.6445.2055.29650.97351.45610.1896.5535.35.179-29.1375.77111.88821.278-587.00915.33614.49613.0970000
Operating Expenses 581.674610.043609.948986.175947.41940.677870.5081,021.837862.947-546.087856.379871.558795.43-485.268813.609808.524817.775-514.21850.989891.502866.599-587.009962.338887.522845.4090000
Operating Income 243.431338.036268.168221.607202.078211.327-0.979-114.799271.133348.943323.111133.033210.89264.662176.565163.78416.049388.961407.639340.818455.895601.486483.79488.322438.6390000
Operating Income Ratio 0.0680.0770.0590.0560.0510.054-0-0.030.0670.0730.0730.0360.0550.0760.0470.0380.0040.0690.0630.0590.0790.0760.0660.0670.0830000
Total Other Income Expenses Net -194.26-226.911-243.603-205.192-171.494-196.691-174.638-209.93-210.023-169.107-170.945-129.121-205.999-621.881-299.79-273.535-273.524-305.249-304.976-314.959-293.419-372.218-344.641-421.039-286.1390000
Income Before Tax 49.171111.12524.56516.41530.58414.636-175.617-324.72961.11179.831152.1663.9124.891-357.219-123.225-109.751-257.47583.712102.66325.859162.476229.268139.14967.283152.50000
Income Before Tax Ratio 0.0140.0250.0050.0040.0080.004-0.051-0.0840.0150.0380.0340.0010.001-0.102-0.033-0.026-0.0660.0150.0160.0040.0280.0290.0190.0090.0290000
Income Tax Expense 19.48105.2058.8966.26212.38-21.738-82.738-100.01122.11663.23854.852-14.701-13.04952.52-42.514-36.61-88.4369.51820.4891.35525.45854.20730.0888.23719.6680000
Net Income 29.6915.92415.66910.15318.20436.373-92.879-224.71838.994116.60397.31418.61317.94-409.749-80.711-73.141-169.03974.19482.17424.504137.018175.061109.06159.046132.8320000
Net Income Ratio 0.0080.0010.0030.0030.0050.009-0.027-0.0580.010.0240.0220.0050.005-0.117-0.021-0.017-0.0430.0130.0130.0040.0240.0220.0150.0080.0250000
EPS 0.130.030.070.0450.0810.16-0.41-10.170.520.430.080.08-1.83-0.36-0.33-0.750.330.370.110.610.790.490.260.590.320.780.740.75
EPS Diluted 0.130.030.070.0450.0810.16-0.41-10.170.520.430.080.08-1.83-0.36-0.33-0.750.330.370.110.610.790.490.260.590.320.730.740.75
EBITDA 398.034485.037421.903374.73360.134359.813146.85933.114421.729313.957471.19325.547405.126-213.372334.132320.012171.738200.258565.688490.436641.208160.431667.902658.27614.6670000
EBITDA Ratio 0.1110.110.0930.0940.0910.0930.0430.0090.1050.0660.1060.0890.105-0.0610.0890.0750.0440.0350.0870.0850.1110.020.0910.0910.1160000